We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




AI Tool for Automatic Colorectal Cancer Tissue Analysis Outperforms Prior Methods

By LabMedica International staff writers
Posted on 26 Oct 2023
Print article
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)
Image: A new AI tool outperforms prior methods in colorectal cancer analysis (Photo courtesy of 123RF)

Colorectal Cancer (CRC) ranks as the third most prevalent and the second most lethal cancer. Catching it early and treating it promptly are extremely important. While machine vision technologies have seen remarkable improvements in automatically classifying types of cancer, they largely rely on deep neural networks with millions of parameters fine-tuned for diagnostic and prognostic tasks. Even though deep learning has shown extraordinary capabilities, healthcare professionals still have to inspect biopsied tissue samples to verify the diagnosis and assess the stage of the tumor. To advance this field further, scientists have now introduced an artificial intelligence (AI) solution specifically designed for automated analysis of colorectal cancer tissue that outperforms previous techniques.

The refined neural network developed by researchers from the University of Jyväskylä (Jyväskylä, Finland) has set new performance benchmarks in colorectal cancer tissue analysis. The AI-based system offers a more accurate and quicker way to categorize tissue samples of colorectal cancer from microscope slides. This advancement could significantly ease the work burden on histopathologists, thus enabling faster and more precise prognoses and diagnoses. Despite the promising results, it is important to be cautious while incorporating AI into medical practice.

As AI technologies move closer to becoming a standard part of clinical procedures, it becomes increasingly vital that they go through rigorous clinical validation. This is to ensure that the results they produce are consistently in line with established clinical norms. In a move encouraging collaborative development, the researchers are making this trained neural network publicly available. Their aim is to accelerate progress in the field by allowing scientists, researchers, and developers from around the world to further refine the tool and explore its various potential applications.

“By granting universal access, the aim is to fast-track breakthroughs in colorectal cancer research,” said Fabi Prezja, who was responsible for the design of the method.

Related Links:
University of Jyväskylä 

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Typhoid Rapid Test
OnSite Typhoid IgG/IgM Combo Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.